Skip to main content
NASDAQ:FORA

Forian Competitors

$10.00
+0.10 (+1.01 %)
(As of 05/18/2021 12:19 PM ET)
Add
Compare
Today's Range
$10.00
$10.13
50-Day Range
$9.39
$12.85
52-Week Range
$9.28
$45.00
Volume272 shs
Average Volume93,829 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Forian (NASDAQ:FORA) Vs. ADTX, CBDC, BFLY, CANB, CBGL, and MTBCP

Should you be buying FORA stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Forian, including ADiTx Therapeutics (ADTX), Apotheca Biosciences (CBDC), Butterfly Network (BFLY), Can B (CANB), Cannabis Global (CBGL), and CareCloud (MTBCP).

Forian (NASDAQ:FORA) and ADiTx Therapeutics (NASDAQ:ADTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Forian and ADiTx Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forian0000N/A
ADiTx Therapeutics00103.00

Profitability

This table compares Forian and ADiTx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ForianN/AN/AN/A
ADiTx TherapeuticsN/AN/AN/A

Earnings and Valuation

This table compares Forian and ADiTx Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ForianN/AN/AN/AN/AN/A
ADiTx TherapeuticsN/AN/AN/AN/AN/A

Summary

ADiTx Therapeutics beats Forian on 1 of the 1 factors compared between the two stocks.

Forian (NASDAQ:FORA) and Apotheca Biosciences (NASDAQ:CBDC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Forian and Apotheca Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forian0000N/A
Apotheca Biosciences0000N/A

Profitability

This table compares Forian and Apotheca Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ForianN/AN/AN/A
Apotheca BiosciencesN/AN/AN/A

Earnings and Valuation

This table compares Forian and Apotheca Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ForianN/AN/AN/AN/AN/A
Apotheca BiosciencesN/AN/AN/AN/AN/A

Forian (NASDAQ:FORA) and Butterfly Network (NASDAQ:BFLY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Forian and Butterfly Network, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forian0000N/A
Butterfly Network0000N/A

Profitability

This table compares Forian and Butterfly Network's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ForianN/AN/AN/A
Butterfly NetworkN/AN/AN/A

Earnings and Valuation

This table compares Forian and Butterfly Network's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ForianN/AN/AN/AN/AN/A
Butterfly NetworkN/AN/AN/AN/AN/A

Forian (NASDAQ:FORA) and Can B (NASDAQ:CANB) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Forian and Can B, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forian0000N/A
Can B0000N/A

Profitability

This table compares Forian and Can B's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ForianN/AN/AN/A
Can BN/AN/AN/A

Earnings and Valuation

This table compares Forian and Can B's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ForianN/AN/AN/AN/AN/A
Can BN/AN/AN/AN/AN/A

Forian (NASDAQ:FORA) and Cannabis Global (NASDAQ:CBGL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Forian and Cannabis Global, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forian0000N/A
Cannabis Global0000N/A

Profitability

This table compares Forian and Cannabis Global's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ForianN/AN/AN/A
Cannabis GlobalN/AN/AN/A

Earnings and Valuation

This table compares Forian and Cannabis Global's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ForianN/AN/AN/AN/AN/A
Cannabis GlobalN/AN/AN/AN/AN/A

Forian (NASDAQ:FORA) and CareCloud (NASDAQ:MTBCP) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings for Forian and CareCloud, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Forian0000N/A
CareCloud0000N/A

Profitability

This table compares Forian and CareCloud's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ForianN/AN/AN/A
CareCloudN/AN/AN/A

Earnings and Valuation

This table compares Forian and CareCloud's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ForianN/AN/AN/AN/AN/A
CareCloudN/AN/AN/AN/AN/A


Forian Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.27+3.1%$0.00N/A0.00Earnings Announcement
Gap Up
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.06+0.0%$0.00N/A0.00Gap Down
BFLY
Butterfly Network
0.5$10.09+4.0%$0.00N/A0.00
Can B logo
CANB
Can B
0.4$0.40+2.5%$0.00N/A0.00
Cannabis Global logo
CBGL
Cannabis Global
0.0$0.10+0.0%$0.00N/A0.00Gap Up
CareCloud logo
MTBCP
CareCloud
0.3$28.38+0.2%$0.00N/A0.00Dividend Announcement
Cognyte Software logo
CGNT
Cognyte Software
1.3$23.87+0.3%$0.00N/A0.00
Corner Growth Acquisition logo
COOL
Corner Growth Acquisition
0.8$9.70+1.0%$0.00N/A0.00News Coverage
FLGC
Flora Growth
0.0$3.44+4.1%$0.00N/A0.00News Coverage
Green Hygienics logo
GRYN
Green Hygienics
0.0$1.05+9.5%$0.00N/A0.00Gap Up
GLSI
Greenwich LifeSciences
2.0$32.52+1.1%$0.00N/A0.00
Medigus logo
MDGS
Medigus
1.7$1.71+1.2%$0.00N/A0.00News Coverage
Movano logo
MOVE
Movano
0.5$5.02+0.4%$0.00N/A0.00High Trading Volume
Prometheus Biosciences logo
RXDX
Prometheus Biosciences
2.0$19.11+7.2%$0.00N/A0.00Earnings Announcement
News Coverage
Gap Up
SCPS
Scopus BioPharma
1.4$5.71+0.7%$0.00N/A0.00
The Greater Cannabis logo
GCAN
The Greater Cannabis
0.6$0.01+0.0%$0.00N/A0.00Gap Up
VERA
Vera Therapeutics
0.0$11.95+2.5%$0.00N/A0.00High Trading Volume
Gap Down
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.